Dr. Robert D. Bona, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- State University of Ny Upstate Medical University (1980)
- Years since graduation
- 46
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 98
Licensed in Connecticut since 1984, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1980Medical school: State University of Ny Upstate Medical University
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CT license 026000 (first issued 1984; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Yale-New Haven Hospital New Haven, CT
Medical groups
- Yale University (2,645 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 98
- Services billed
- 136
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 74 | 57 |
| Established patient office or other outpatient visit, 30-39 minutes | 42 | 27 |
| Established patient office or other outpatient visit, 40-54 minutes | 15 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Farmington, CT | 165 |
| Xarelto (rivaroxaban) Other prescribers in Farmington, CT | 56 |
| Cerezyme (imiglucerase) | 19 |
| Cerdelga (eliglustat tartrate) | 17 |
| Enoxaparin Sodium Other prescribers in Farmington, CT | 16 |
| Hydroxyurea Other prescribers in Farmington, CT | 12 |
| Warfarin Sodium Other prescribers in Farmington, CT | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 2 payments worth $1,725 in total to this clinician.
| Pfizer Inc. | $1,725 |
|---|
| Consulting Fee | $1,725 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. May 28, 2025 | Consulting Fee | $1,150 |
| Pfizer Inc. Dec 1, 2025 | Consulting Fee | $575 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $160,519 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or Relapsed After First …
Novartis Pharmaceuticals Corporation - A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05568459
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.